{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T07:20:07Z","timestamp":1777706407638,"version":"3.51.4"},"reference-count":33,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Arch Allergy Immunol"],"published-print":{"date-parts":[[2015]]},"abstract":"<b><i>Background:<\/i><\/b> House dust mite (HDM) immunotherapy has proven efficacy in treating allergic rhinitis (AR) symptoms. This trial evaluated the dose-response relationship of SLITone<sup>ULTRA<\/sup>\u00ae HDM mix based on immunological parameters and safety in subjects with moderate-to-severe HDM AR not controlled by symptomatic medication. <b><i>Materials and Methods:<\/i><\/b> A randomized, parallel-group, open-label, clinical trial compared 50\/150\/300 standard reactivity unit (SRU) doses of SLITone<sup>ULTRA<\/sup>\u00ae HDM mix for 6 months. Subjects had moderate-to-severe HDM AR, positive skin prick and IgE against <i>Dermatophagoides pteronyssinus\/Dermatophagoides farinae<\/i> (DP\/DF). The primary end point was change from baseline in the IgE-blocking factor against DP after 6 months. Secondary end points measured changes in the IgE-blocking factor for DP at 3 months and for DF at 3 and 6 months, and in IgG<sub>4<\/sub> and specific IgE to DP\/DF after 3 and 6 months. Tolerability was assessed through the evaluation of all adverse events (AEs). <b><i>Results:<\/i><\/b> A total of 219 subjects were randomized and 196 completed the trial. Dose effect was significant on DP IgE-BF after 6 months (p = 0.018). The change in the DP IgE-blocking factor at a 300-SRU dose was higher than at other doses after 3 (p = 0.008) and 6 (p = 0005) months of treatment. Similar changes were observed for IgG<sub>4<\/sub> and allergen-specific IgE. The number of AEs increased with the dose and were mild-to-moderate, with no severe treatment-related AEs reported. The most frequent AEs were oral\/tongue pruritus, mouth oedema and abdominal upper pain. <b><i>Conclusions:<\/i><\/b> Data showed a dose-response for immunological markers and safety with a better immunological response for 300 SRU. The highest dose (300 SRU daily) was considered as the optimal maintenance dose.<\/jats:p>","DOI":"10.1159\/000442467","type":"journal-article","created":{"date-parts":[[2016,1,20]],"date-time":"2016-01-20T22:02:43Z","timestamp":1453327363000},"page":"182-192","source":"Crossref","is-referenced-by-count":12,"title":["Dose-Dependent Immunological Responses after a 6-Month Course of Sublingual House Dust Mite Immunotherapy in Patients with Allergic Rhinitis"],"prefix":"10.1159","volume":"168","author":[{"given":"Alain","family":"Didier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paloma","family":"Campo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Durand-Perdriel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Marin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Chartier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2016,1,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.04.00013904"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2003.11.015"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2745.2002.01461.x"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2007.28.2934"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2007.02714.x"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2007.01549.x"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0b013e3282f3f42f"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa023171"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2006.01002.x"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.11.030"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2008.02976.x"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2006.01068.x"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.121317"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2007.01451.x"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)60211-6"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.2001.01027.x"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002893"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.12.586"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12039"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.09.004"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(98)70271-4"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1993.tb01791.x"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.12.1080"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2010.02451.x"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2011.02745.x"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.10.044"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2008.03020.x"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2007.01620.x"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.11.012"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.12.1358"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2006.00959.x"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2007.01402.x"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.05.003"}],"container-title":["International Archives of Allergy and Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/442467","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/442467","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/442467","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:09:19Z","timestamp":1745431759000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000442467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,3,1]]},"published-print":{"date-parts":[[2016,3,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000442467","archive":["Portico"],"relation":{},"ISSN":["1018-2438","1423-0097"],"issn-type":[{"value":"1018-2438","type":"print"},{"value":"1423-0097","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}